The department focuses on female and male infertility and is pursuing research on clinical and molecular aspects of frequently encountered conditions viz. polycystic ovarian syndrome (PCOS); premature ovarian failure (POF); endometriosis; severe oligoasthenozoospermia and non-obstructive azoospermia to develop improved diagnostic and therapeutic tools. Studies on PCOS have confirmed that the syndrome, if untreated, can have other long term health implications such as dyslipidemia, increased risk of cardiovascular disease and non-insulin-dependent diabetes mellitus. Genes associated with POF (menopause before the age of 40 years) are being screened for mutations in affected women and their family members. This will help to counsel individuals, genetically predisposed to POF and still menstruating, for adoption of measures to preserve their ovarian function. The department is also investigating the causes of low sperm count using state-of-art molecular methodologies. The faculty associates with training programmes for WHO in-country fellows.The research interests of this group are research on newer contraceptives including, IUCDs, injectables, microbicides and other therapeutics for improving reproductive health. Clinical trials have been conducted for emergency contraceptive pills which have now been included in the National Family Welfare Programme. In addition, Studies on intrauterine contraceptive devices revealed that CuT 380 is an effective long term contraceptive and is now placed in the Family Planning program of India. Clinical and acceptability studies with injectable contraceptives are also carried to further facilitate the expansion of the contraceptive choice basket . Studies are underway to assess the safety, efficacy and acceptability of various contraceptive methods and to optimize their use within the prevailing health care infrastructure in the urban and rural setups.
Guidelines for diagnosis and management of reproductive tract infections at primary health care level have been developed. The department has conducted Phase-I and II clinical trials to assess safety and efficacy of microbicides.
The institute also undertook WHO collaborative Research to develop an optimal and effective dosage for first and second trimester abortions and also study the utility of misoprostol as a cervical ripening agent. These studies are undertaken in collaboration with the nearby medical Colleges and hospitals. These study results in conjunction with other national studies have culminated in granting approval for medical methods for termination of pregnancies with less than 7 weeks of gestation subsequent to amendment of the MTP act of the country. Other studies are being pursued on provision of safe abortion services as well as understanding the reasons for repeated abortions by the women.
Clinical research group has also conducted studies on the prevalence of menopausal symtomatology, and sexuality aspects in menopausal women. Focus of research to study the extent of osteoporosis among women with therapeutic options, prevalence of osteoporosis among different socio-economic strata, across ages and in both men and women has also been addressed. Intervention studies to improve the bone health by increasing the bone mineral density are also being dealt with.
Community based regular orientation workshops for medical officers and nurses are carried out in the corporation health posts and nursing students are conducted on relevant issues.
The clinicians develop active collaborative projects with the basic scientists at the institute for which clinic clientele are motivated to participate in the studies following informed consent.
The institute has been providing services for the cervical cancer screening by pap smear to women attending various clinics for the last three decades. The institute has also developed criteria to detect five reproductive tract infections viz Bacterial Vaginosis, Candida, Chlamydia trachomatis, Human Papilloma Virus, Herpes Simplex Virus in pap smear which could be useful in low resource settings where sensitive laboratory tests are not available.
Department Email Id: firstname.lastname@example.org
|Dr S L Chauhan||Scientist G|
|Dr. Lalita Savardekar||Scientist E|
|Dr A D Patil||Scientist E|
|Dr R Gajbhiye||Scientist D|
|Dr S Surve||Scientist C|
|Dr K Munne||Scientist B|
|Dr Deepti Tandon||Scientist B|
|Dr Periyasamy Kuppusamy||Scientist B|
|Dr. Vrushali Palayekar||Technical Officer A|
|Mrs. V. Tryambake||Technical Officer A|
|Mr. A D Vadigopulla||Technical Officer A|
|Mrs. Pratibha Kokate||Technical Officer A|
|Dr. S A Khan||Technical Assistant|
|Mrs L Tendulkar||Technical Assistant|
|Mrs S Kamat||Technician A|
|Mrs. R Dalvi||Nurse|
|Mrs. S Kale||Nurse|
|Mrs R Pednekar||Nurse|
|Mrs A Akula||Technician C|
|Mrs. S Kharat||Technician C|
|Mrs. S Ghag||Attendant Services|
|Mrs. S Kendre||Attendant Services|
1. Contraceptive knowledge and practices among abortion seekers (Funded by NIRRH)
2. Reproductive tract infections- a clinical and microbiological study in women (Funded by WHO in country)
3. Determination of the prevalence of Osteoporosis in Indian women by DEXA technique: Therapeutic intervention in high- risk women.
4. Evaluation of menopausal symptomatology in peri- menopausal women. (Funded by NIRRH)
5. Acceptability and Continuation Rate of Two-monthly Injectable contraceptive: Norethisterone Enanthate (Funded by Ministry of Health and Family Welfare, Government of India)
6. Bone Mass Density Evaluation by Dexa among injection Norethisterone- Enanthate Users (Funded by Ministry of Health and Family Welfare)
7. Comparison of two doses and two routes of administration of Misoprostol after pre-treatment with Mifepristone for early pregnancy termination (Funded by WHO).
8. Elucidation of the role of progesterone in cervical ripening in rats(Funded by Department of Science and Technology)
9. Assessment of the prevalence of Osteoporosis in adult population in India (Funded by ICMR)